These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30901208)

  • 21. Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif.
    Guan P; Wang L; Hou X; Wan Y; Xu W; Tang W; Fang H
    Bioorg Med Chem; 2014 Nov; 22(21):5766-75. PubMed ID: 25311567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis and biological evaluation of novel histone deacetylase inhibitors incorporating 4-aminoquinazolinyl systems as capping groups.
    Zhang Q; Li Y; Zhang B; Lu B; Li J
    Bioorg Med Chem Lett; 2017 Nov; 27(21):4885-4888. PubMed ID: 28947154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
    Zang J; Liang X; Huang Y; Jia Y; Li X; Xu W; Chou CJ; Zhang Y
    J Med Chem; 2018 Jun; 61(12):5304-5322. PubMed ID: 29787262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy.
    Zhang M; Wei W; Peng C; Ma X; He X; Zhang H; Zhou M
    Bioorg Med Chem Lett; 2021 Oct; 49():128286. PubMed ID: 34314844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Macrocyclic compounds as anti-cancer agents: design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2.
    Ning CQ; Lu C; Hu L; Bi YJ; Yao L; He YJ; Liu LF; Liu XY; Yu NF
    Eur J Med Chem; 2015 May; 95():104-15. PubMed ID: 25800646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The promise of Janus kinase inhibitors in the treatment of hematological malignancies.
    Senkevitch E; Durum S
    Cytokine; 2017 Oct; 98():33-41. PubMed ID: 28277287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
    Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
    Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies.
    Lu D; Wang C; Qu L; Yin F; Li S; Luo H; Zhang Y; Liu X; Chen X; Luo Z; Cui N; Kong L; Wang X
    J Med Chem; 2022 Oct; 65(19):12838-12859. PubMed ID: 36153841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
    Cheng C; Yun F; He J; Ullah S; Yuan Q
    Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of adamantane based highly potent HDAC inhibitors.
    Gopalan B; Ponpandian T; Kachhadia V; Bharathimohan K; Vignesh R; Sivasudar V; Narayanan S; Mandar B; Praveen R; Saranya N; Rajagopal S; Rajagopal S
    Bioorg Med Chem Lett; 2013 May; 23(9):2532-7. PubMed ID: 23538115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of N-hydroxybenzamide derivatives with indole-containing cap group as histone deacetylases inhibitors.
    Li X; Wu J; Li X; Mu W; Liu X; Jin Y; Xu W; Zhang Y
    Bioorg Med Chem; 2015 Oct; 23(19):6258-70. PubMed ID: 26349626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
    Cui H; Hong Q; Wei R; Li H; Wan C; Chen X; Zhao S; Bu H; Zhang B; Yang D; Lu T; Chen Y; Zhu Y
    Eur J Med Chem; 2022 Feb; 229():114049. PubMed ID: 34954594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and preliminary bioactivity evaluations of substituted quinoline hydroxamic acid derivatives as novel histone deacetylase (HDAC) inhibitors.
    Wang L; Hou X; Fu H; Pan X; Xu W; Tang W; Fang H
    Bioorg Med Chem; 2015 Aug; 23(15):4364-4374. PubMed ID: 26149591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
    Chen Y; Wang X; Xiang W; He L; Tang M; Wang F; Wang T; Yang Z; Yi Y; Wang H; Niu T; Zheng L; Lei L; Li X; Song H; Chen L
    J Med Chem; 2016 Jun; 59(11):5488-504. PubMed ID: 27186676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of novel selective Janus kinase 2 (JAK2) inhibitors bearing a 1H-pyrazolo[3,4-d]pyrimidin-4-amino scaffold.
    Yin Y; Chen CJ; Yu RN; Shu L; Zhang TT; Zhang DY
    Bioorg Med Chem; 2019 Apr; 27(8):1562-1576. PubMed ID: 30846405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms.
    Hao X; Xing W; Yuan J; Wang Y; Bai J; Bai J; Zhou Y
    Invest New Drugs; 2020 Jun; 38(3):610-620. PubMed ID: 31227936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of novel ferulic acid derivatives as potent histone deacetylase inhibitors.
    Wang F; Lu W; Zhang T; Dong J; Gao H; Li P; Wang S; Zhang J
    Bioorg Med Chem; 2013 Nov; 21(22):6973-80. PubMed ID: 24095016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis, biological evaluation and molecular docking studies of 3-(1,3-diphenyl-1H-pyrazol-4-yl)-N-phenylacrylamide derivatives as inhibitors of HDAC activity.
    Li X; Liu JL; Yang XH; Lu X; Zhao TT; Gong HB; Zhu HL
    Bioorg Med Chem; 2012 Jul; 20(14):4430-6. PubMed ID: 22705022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, Synthesis and Biological Evaluation of Novel Benzoylimidazole Derivatives as Raf and Histone Deacetylases Dual Inhibitors.
    Chen X; Gong G; Chen X; Song R; Duan M; Qiao R; Jiao Y; Qi J; Chen Y; Zhu Y
    Chem Pharm Bull (Tokyo); 2019; 67(10):1116-1122. PubMed ID: 31582631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.